



US009764003B2

(12) **United States Patent**
Jensen(10) **Patent No.:** **US 9,764,003 B2**
(45) **Date of Patent:** **Sep. 19, 2017**(54) **USE OF LONG-ACTING GLP-1 PEPTIDES**(71) Applicant: **Novo Nordisk A/S, Bagsvaerd (DK)**(72) Inventor: **Christine B. Jensen, Charlottenlund (DK)**(73) Assignee: **Novo Nordisk A/S, Bagsvaerd (DK)**

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/409,493**(22) PCT Filed: **Jun. 21, 2013**(86) PCT No.: **PCT/EP2013/063004**

§ 371 (c)(1),

(2) Date: **Dec. 19, 2014**(87) PCT Pub. No.: **WO2014/005858**PCT Pub. Date: **Jan. 9, 2014**(65) **Prior Publication Data**

US 2015/0190474 A1 Jul. 9, 2015

Related U.S. Application Data

(60) Provisional application No. 61/694,837, filed on Aug. 30, 2012, provisional application No. 61/708,162, filed on Oct. 1, 2012.

(30) **Foreign Application Priority Data**Jul. 1, 2012 (EP) 12174535
Oct. 1, 2012 (EP) 12186781(51) **Int. Cl.****A61K 38/26** (2006.01)**A61P 5/50** (2006.01)**A61P 3/04** (2006.01)**A61P 3/10** (2006.01)(52) **U.S. Cl.**CPC **A61K 38/26** (2013.01)(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited****U.S. PATENT DOCUMENTS**8,129,343 B2 3/2012 Lau et al.
8,536,122 B2 9/2013 Lau et al.
2010/0047762 A1 2/2010 Button et al.
2010/0292133 A1 11/2010 Spetzler et al.
2011/0301080 A1 12/2011 Bush et al.**FOREIGN PATENT DOCUMENTS**CN 102229668 11/2011
CN 102229668 A 11/2011DK WO 2006097537 A2 * 9/2006 C07K 14/605
RU 2409349 C2 1/2011
RU 2413530 C2 3/2011
WO 2010/092163 A2 8/2010
WO 2011/080103 A1 7/2011
WO 2011/138421 A1 11/2011
WO 2012/016419 A1 2/2012
WO 2012/080471 A1 6/2012
WO 2012/107476 A1 8/2012
WO 2012/130136 A1 10/2012
WO 2012/136790 A1 10/2012
WO 2012/177929 A2 12/2012**OTHER PUBLICATIONS**Kim et al., "Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes," *Diabetes Care* 30:1487-1493 (2007).*

Bydureon NDA 022200/S-008 package information, pp. 1-179 (Feb. 2014).*

Clinical Trial NCT00696657, entitled "A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide," pp. 1-5 (Mar. 11, 2015)—accessed Sep. 24, 2015 at URL clinicaltrials.gov/archive/NCT00696657/2011_03_25.*Lau et al., "Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide," *J. Med. Chem.* 58:7370-7380 (2015).*Eperzan assessment report, Euro. Med. Agency, pp. 1-124 (2014)—accessed Sep. 24, 2015 at URL: ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002735/WC500165119.pdf.*Trulicity assessment report, Euro. Med. Agency, pp. 1-172 (2014)—accessed Sep. 24, 2015 at URL: ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002825/WC500179473.pdf.*CDC, "Nathional Health and Nutrition Examination Survey: Healthy weight, overweight, and obesity among U.S. adults," 03-0260, pp. 1-2 (Jul. 2003) accessed May 10, 2016 at URL cdc.gov/nchs/data/nhanes/databriefs/adultweight.pdf.*Madsbad S et al. An Overview of once-weekly glucagon-like peptide-1 receptor agonists available efficacy and safety data and perspectives for the future, *Diabetes, Obesity and Metabolism* Year 2011, vol. 13, No. 5, pp. 394-407.Buse B. J. et al., Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study, *Lancet*, 2013, vol. 381, pp. 117-124.
Mizuta et al. "The Role for GLP-1 in Regulation of Body Weight." *Progress in Medicine* 2008 vol. 28 No. 8 pp. 1909-1912.

* cited by examiner

Primary Examiner — Julie Ha*Assistant Examiner* — Kristina M Hellman(74) *Attorney, Agent, or Firm* — Leon Y. Lum(57) **ABSTRACT**

The invention relates to use of long-acting GLP-1 peptides in certain dosage regimes for the treatment of type 2 diabetes, obesity, etc.

6 Claims, 6 Drawing Sheets